Announcement PDF BPH GLOBAL LTD ACN 009 104 330 7 November 2025 Company Announcements Platform Australian Securities Exchange BPH Global Strengthens Advisory Board - Appoints Ms Ifat Mazouz to Drive R&D Commercialisation Strategy Highlights ● Appointment of Ms Ifat Mazouz as additional member of BP8’s Advisory Board. ● Ms Mazouz is an accomplished aquaculture executive with nearly two decades of international experience in marine biotechnology, aquaculture systems, and sustainable innovation. ● Brings deep expertise in transitioning R&D programs from laboratory to large-scale commercial deployment. ● Strengthens the Advisory Board’s capability to assess commercial feasibility, market readiness, and strategic value creation across BP8’s entire portfolio of research and development initiatives. ● Expands the Company’s ability to integrate scientific innovation with viable commercialisation pathways in biotechnology, nutraceuticals, and environmental remediation. Appointment of Ms Ifat Mazouz The Board of BPH Global Ltd (ASX: BP8) (BP8 or Company) is pleased to announce the appointment of Ms Ifat Mazouz as the second member of its Advisory Board, effective 1 November 2025. Ms Mazouz joins Dr Ellyn Erlania, the inaugural member of the Advisory Board, broadening the Board’s expertise to encompass both scientific innovation and commercial execution. In September, the Company announced the formation of its R&D Advisory Board. A marine biotechnology professional based in Singapore, Ms Mazouz has nearly twenty years of experience spanning aquaculture research, marine system design, regulatory compliance, product development, and technology commercialisation. Her career includes senior leadership and consultancy roles across Asia and the Middle East, integrating cross-disciplinary R&D with high- performance industrial operations. BP8 Chairman Paul Stephenson said: “Ifat’s appointment further strengthens BP8’s ability to convert research potential into sustainable commercial success. Her background in building aquaculture ventures from concept to market, coupled with her scientific and operational expertise, will provide valuable insight as BP8 continues to advance and diversify its R&D programs.” Scope of Advisory Role Under her engagement agreement, Ms Mazouz will provide strategic advice to the Company across the following areas: • Research oversight: assisting BP8, including liaison with Gaia Mariculture Pte Ltd (the Company’s Singapore-based R&D consultant), in overseeing the Company’s existing R&D projects. • Sourcing new R&D opportunities: identifying and evaluating potential projects with commercial promise. • Global seaweed and aquaculture industry trends: monitoring advances in cultivation, processing, biotechnology, and related market applications. • Strategic partnerships: supporting collaboration opportunities with industry, academic institutions, and government bodies. • Capital and grant opportunities advising on available government programs and funding to support R&D growth and commercialisation. BP8’s Current R&D Portfolio BP8 Global is currently advancing a diversified range of biotechnology and environmental R&D initiatives, including: • Bio-stimulant formulation development for agricultural applications. • Probiotic and post-biotic kefir beverages targeting functional-food and wellness markets. • Men’s sexual-health and performance formulations under nutraceutical development. • Seaweed mineral identification and extraction for value-added marine resources. • Bioremediation of coastal and inland waterways using biological and microbial processes. With the addition of Ms Mazouz, the Advisory Board will guide BP8 in aligning its research priorities with sustainable commercial outcomes. Terms of Appointment • Effective Date: 1 November 2025. • Term: Initial one-year appointment, renewable by mutual consent. • Fee: SGD 2,000 (≈ AUD 2,360) per month. • Benefits: One Company-sponsored trip annually to attend an advisory seminar in Singapore, Indonesia, or Australia. • Termination: Either party may terminate with 30 days’ written notice. • Governing Law: Australia. About Ifat Mazouz Ms Mazouz is an accomplished aquaculture scientist and executive with a strong record of innovation and leadership across the marine biotechnology sector. Her most recent appointment was as Chief Scientific Officer of Vertical Oceans (Singapore), where she established the company’s scientific strategy, R&D infrastructure, and integrated aquaculture systems, guiding the transition from concept to commercial production. Her previous roles include senior research and operational leadership positions with Phibro Animal Health Care, the Marine Aquaculture Centre at Ruppin Academic Centre, and Seakura Ltd, where she directed macroalgae-based production and regulatory programs. She has also provided scientific and strategic consultancy services to government and private-sector clients across the food-tech, biotech, and aquaculture industries. Ms Mazouz holds a Master of Science in Marine Sciences from Bar Ilan University, specialising in coral reef physiology and biochemistry, and a Bachelor of Science in Marine Sciences from Ruppin Academic Centre. Her professional expertise spans marine system engineering, bioprocess optimisation, regulatory compliance, intellectual property strategy, and cross-functional team leadership. – ENDS – Authorised for release by: The Board of BPH Global Ltd For further information, please visit our website at www.bphglobal.com or contact the Company Secretary on 03 9088 2049.